tetano
Editor, Senior Moderator
Phytomedicine. 2011 Nov 21. [Epub ahead of print]
Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret(?) against viruses causing respiratory infections.
Glatthaar-Saalm?ller B, Rauchhaus U, Rode S, Haunschild J, Saalm?ller A.
Source
Labor Dr. Glatthaar, Beim Braunland 1, D-88416 Ochsenhausen, Germany; Institute of Immunology, Department for Pathobiology, University of Veterinary Medicine Vienna, Veterin?rplatz 1, A-1210 Vienna, Austria.
Abstract
Sinupret(?), a herbal medicinal product made from Gentian root, Primula flower, Elder flower, Sorrel herb, and Verbena herb is frequently used in the treatment of acute and chronic rhinosinusitis and respiratory viral infections such as common cold. To date little is known about its potential antiviral activity. Therefore experiments have been performed to measure the antiviral activity of Sinupret(?) oral drops (hereinafter referred to as "oral drops") and Sinupret(?) dry extract (hereinafter referred to as "dry extract"), in vitro against a broad panel of both enveloped and non-enveloped human pathogenic RNA and DNA viruses known to cause infections of the upper respiratory tract: influenza A, Chile 1/83 (H1N1) virus (FluA), Porcine Influenza A/California/07/2009 (H1N1) virus (pFluA), parainfluenza type 3 virus (Para 3), respiratory syncytial virus, strain Long (RSV), human rhinovirus B subtype 14 (HRV 14), coxsackievirus subtype A9 (CA9), and adenovirus C subtype 5 (Adeno 5). Concentration-dependent antiviral activity (EC(50) between 13.8 and 124.8μg/ml) of Sinupret(?) was observed against RNA as well as DNA viruses independent of a viral envelope. Remarkable antiviral activity was shown against Adeno 5, HRV 14 and RSV in which dry extract was significantly superior to oral drops. This could be ascertained with different assays as plaque-reduction assays in plaque forming units (PFU), the analyses of a cytopathogenic effect (CPE) and with enzyme immunoassays (ELISA) to determine the amount of newly synthesised virus. Our results demonstrate that Sinupret(?) shows a broad spectrum of antiviral activity in vitro against viruses commonly known to cause respiratory infections.
Copyright ? 2011 Elsevier GmbH. All rights reserved.
PMID:
22112724
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22112724
Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret(?) against viruses causing respiratory infections.
Glatthaar-Saalm?ller B, Rauchhaus U, Rode S, Haunschild J, Saalm?ller A.
Source
Labor Dr. Glatthaar, Beim Braunland 1, D-88416 Ochsenhausen, Germany; Institute of Immunology, Department for Pathobiology, University of Veterinary Medicine Vienna, Veterin?rplatz 1, A-1210 Vienna, Austria.
Abstract
Sinupret(?), a herbal medicinal product made from Gentian root, Primula flower, Elder flower, Sorrel herb, and Verbena herb is frequently used in the treatment of acute and chronic rhinosinusitis and respiratory viral infections such as common cold. To date little is known about its potential antiviral activity. Therefore experiments have been performed to measure the antiviral activity of Sinupret(?) oral drops (hereinafter referred to as "oral drops") and Sinupret(?) dry extract (hereinafter referred to as "dry extract"), in vitro against a broad panel of both enveloped and non-enveloped human pathogenic RNA and DNA viruses known to cause infections of the upper respiratory tract: influenza A, Chile 1/83 (H1N1) virus (FluA), Porcine Influenza A/California/07/2009 (H1N1) virus (pFluA), parainfluenza type 3 virus (Para 3), respiratory syncytial virus, strain Long (RSV), human rhinovirus B subtype 14 (HRV 14), coxsackievirus subtype A9 (CA9), and adenovirus C subtype 5 (Adeno 5). Concentration-dependent antiviral activity (EC(50) between 13.8 and 124.8μg/ml) of Sinupret(?) was observed against RNA as well as DNA viruses independent of a viral envelope. Remarkable antiviral activity was shown against Adeno 5, HRV 14 and RSV in which dry extract was significantly superior to oral drops. This could be ascertained with different assays as plaque-reduction assays in plaque forming units (PFU), the analyses of a cytopathogenic effect (CPE) and with enzyme immunoassays (ELISA) to determine the amount of newly synthesised virus. Our results demonstrate that Sinupret(?) shows a broad spectrum of antiviral activity in vitro against viruses commonly known to cause respiratory infections.
Copyright ? 2011 Elsevier GmbH. All rights reserved.
PMID:
22112724
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22112724